glp 1 asa Anesthetic Considerations for Patients Taking Glucagon-Like Peptide-1 Agonists Perioperative management of patients taking

Tirzepatide, an injectable medication for weight loss and diabetes management, is seen as a major advancement, but its affordability remains a concern

That gap is more than $10,000 a year on identical active ingredient

At a high level, what appears to be most tangible about the experience of patients on GLP-1s is an abrupt reduction in cravings and compulsive behaviors and a sense of increased agency: the ability to make conscious decisions about what to consume, whether it is food or other substances, rather than feeling pulled by a strong internal urge

In the 24-week study of patients receiving JANUVIA as add-on therapy to insulin (with or without metformin), there were no adverse reactions reported regardless of investigator assessment of causality in 5% of patients and more commonly than in patients given placebo, except for hypoglycemia (see Table 3)

This program is not designed to diagnose, treat, cure, or prevent any medical condition